1
|
Hoang TC, Nguyen MT, Nguyen TQ, Ho BTQ, Nguyen HT, Ngo TPD, Tran HNK, Bui TKL. In vitro anti-leukemia, antioxidant, and anti-inflammatory properties of Lantana camara. BRAZ J BIOL 2024; 84:e279899. [PMID: 38896728 DOI: 10.1590/1519-6984.279899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 03/31/2024] [Indexed: 06/21/2024] Open
Abstract
It has been demonstrated that Lantana camara possesses several therapeutic properties that can be used to treat various human diseases, including dermatological and gastrointestinal conditions, tetanus, malaria, and tumours. In this investigation, every collected part of L. camara was extracted with absolute methanol to examine its antioxidant capacity using the DPPH assay and its anti-leukemia activity on two AML cell lines, MOLM-13 and MV4-11. In addition, anti-inflammatory effectiveness was evaluated. The results show that extracts from various sections of L. camara have a significant ability to neutralize free radicals, as indicated by their EC50 values. Most of the extracts had values less than 100 μg/ml, with the flower extract having an even lower value of less than 50 μg/ml. Experiments on two AML cell lines showed that the anti-leukemia effects of the extracts were remarkable, with the most potent impact belonging to the root extract (IC50 was 9.78 ± 0.61 and 12.48 ± 1.69 for MOLM-13 and MV4-11 cell lines). The antitumor effect of the extracts was determined to be time- and dose-dependent and did not correlate with antioxidant capacity. Furthermore, when BJ cells were exposed to L. camara root and leaf extracts, their migratory potential was dramatically reduced compared to untreated cells. The extracts demonstrated potential anti-inflammatory capabilities by lowering NO production in LPS-induced BJ cells.
Collapse
Affiliation(s)
- T C Hoang
- Thu Dau Mot University, Department of Medicine and Pharmacy, Thu Dau Mot, Binh Duong, Vietnam
| | - M T Nguyen
- VNU-HCM University of Science, Vietnam National University, Department of Biology and Biotechnology, Ho Chi Minh City, Vietnam
| | - T Q Nguyen
- VNU-HCM University of Science, Vietnam National University, Department of Biology and Biotechnology, Ho Chi Minh City, Vietnam
| | - B T Q Ho
- Ho Chi Minh City Open University, Faculty of Biotechnology, Ho Chi Minh City, Vietnam
| | - H T Nguyen
- Nong Lam University, Faculty of Science, Department of Biology, Ho Chi Minh City, Vietnam
| | - T P D Ngo
- Nguyen Tat Thanh University, NTT Hi-Tech Institute, Ho Chi Minh City, Vietnam
| | - H N K Tran
- Korea Institute of Ocean Science and Technology, Marine Natural Products Chemistry Laboratory, Busan, Republic of Korea
| | - T K L Bui
- Thu Dau Mot University, Department of Medicine and Pharmacy, Thu Dau Mot, Binh Duong, Vietnam
- Institute of Fungal Research and Biotechnology, Southern Key Laboratory of Biotechnology, Hanoi, Vietnam
| |
Collapse
|
2
|
Lim JH, Park CJ, Kim MJ, Jang S, Chi HS, Lee JH, Lee JH, Lee KH, Im HJ, Seo JJ. Generation of lymphocytes potentiated against leukemic lymphoblasts by stimulation using leukemic cell lysate-pulsed dendritic cells in patients with acute lymphoblastic leukemia and measurement of in vitro anti-leukemic cytotoxicity. Hematology 2013; 17:15-22. [DOI: 10.1179/102453312x13221316477453] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- Ji-Hun Lim
- Department of Laboratory MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Chan-Jeoung Park
- Department of Laboratory MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Mi-Jung Kim
- Department of Laboratory MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Sungsoo Jang
- Department of Laboratory MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Hyun-Sook Chi
- Department of Laboratory MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Jung-Hee Lee
- Department of Internal MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Je-Hwan Lee
- Department of Internal MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Kyoo-Hyong Lee
- Department of Internal MedicineUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Ho-Joon Im
- Department of PediatricsUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| | - Jong-Jin Seo
- Department of PediatricsUniversity of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
| |
Collapse
|
3
|
Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H, Valle FD, Treder W, Schmetzer HM. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother 2005; 54:953-70. [PMID: 15789235 PMCID: PMC11032985 DOI: 10.1007/s00262-004-0657-y] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2004] [Accepted: 12/06/2004] [Indexed: 11/30/2022]
Abstract
Functional dendritic cells (DC) are professional antigen presenting cells (APC) and can be generated in vitro from leukemic cells from acute myeloid leukemia AML patients, giving rise to APC of leukemic origin presenting leukemic antigens (DC(leu)). We have already shown that DC can be successfully generated from AML and myeloplastic syndromes (MDS) cells in serum-free 'standard' medium (X-vivo + GM-CSF + IL-4 +TNFalpha + FL) in 10-14 days. In this study, we present that DC counts generated from mononuclear cells (MNC) varied between 20% (from 55 MDS samples), 34% (from 100 AML samples) and 25% (from 38 healthy MNC samples) medium. Between 53% and 58% of DC are mature CD83+ DC. DC harvests were highest in monocytoid FAB types (AML-M4/M5, MDS-CMML) and independent from cytogenetic risk groups, demonstrating that DC-based strategies can be applied for patients with all cytogenetic risk groups. Proof of the clonal derivation of DC generated was obtained in five AML and four MDS cases with a combined FISH/immunophenotype analysis (FISH-IPA): The clonal numerical chromosome aberrations of the diseases were regularly codetectable with DC markers; however, not with all clonal cells being convertible to leukemia-derived DC(leu) (on average, 53% of blasts in AML or MDS). To the contrary, not all DC generated carried the clonal aberration (on average, 51% of DC). In 41 AML and 13 MDS cases with a suitable antigen expression, we could confirm FISH-IPA data by Flow cytometry: although DC(leu) are regularly detectable, on average only 57% of blasts in AML and 64% of blasts in MDS were converted to DC(leu). After coculture with DC in mixed lymphocyte reactions (MLR), autologous T cells from AML and MDS patients proliferate and upregulate costimulatory receptors. The specific lysis of leukemic cells by autologous T cells could be demonstrated in three cases with AML in a Fluorolysis assay. In six cases with only few DC(leu) or few vital T cells available after the DC/MLR procedure, no lysis of allogeneic or autologous leukemic cells was seen, pointing to the crucial role of both partners in the lysis process. We conclude: (1) the generation of DC is regularly possible in AML and also in MDS under serum-free conditions. (2) Clonal/leukemia-derived DC(leu) can be regularly generated from MDS and AML-MNC; however, not with all blasts being converted to DC(leu) and not all DC generated carrying leukemic markers. We recommend to select DC(leu) for vaccinations or ex vivo T-cell activations to avoid contaminations with non-converted blasts and non-leukemia-derived DC and to improve the harvest of specific, anti-leukemic T cells. DC and DC-primed T cells could provide a practical strategy for the immunotherapy of AML and MDS.
Collapse
Affiliation(s)
- S. Kufner
- Medical Department III, Klinikum Grosshadern, University of Munich, Marchioninistr 15, 81377 Munich, Germany
| | - R. Pelka Fleischer
- Medical Department III, Klinikum Grosshadern, University of Munich, Marchioninistr 15, 81377 Munich, Germany
| | - T. Kroell
- Medical Department III, Klinikum Grosshadern, University of Munich, Marchioninistr 15, 81377 Munich, Germany
| | - C. Schmid
- Medical Department III, Klinikum Grosshadern, University of Munich, Marchioninistr 15, 81377 Munich, Germany
| | | | - H. Salih
- Medical Department, University of Tuebingen, Germany
| | | | - W. Treder
- Municipial Hospital Oldenburg, Germany
| | - H. M. Schmetzer
- Medical Department III, Klinikum Grosshadern, University of Munich, Marchioninistr 15, 81377 Munich, Germany
| |
Collapse
|
4
|
Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg DA, Salama A, Seeger K, Moore MAS, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol 2004; 76:623-33. [PMID: 15197237 DOI: 10.1189/jlb.1103581] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells (DC) to induce a leukemia-specific immune response. In this study, three leukemic cell lines were investigated: Kasumi-1 and SKNO-1 (two acute myeloid leukemia (AML) cell lines carrying the (8;21)-chromosomal translocation, resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one) and REH, an acute lymphoblastic leukemia cell line with the (12;21)-chromosomal translocation and expression of translocation ETS-like leukemia-AML1. These fusion proteins are implicated in the pathogenesis of the leukemic state by recruiting corepressors and histone deacetylases (HDAC), which interfere with normal cell differentiation. In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor alpha, granulocyte macrophage-colony stimulating factor, c-kit ligand, and soluble CD40 ligand; yet, addition of the HDAC inhibitor (Hdi) trichostatin A enhanced DC differentiation with retention of the fusion transcripts. These leukemic DC showed high-level CD83 and human leukocyte antigen (HLA)-DR expression and had a high allostimulatory potential. Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42% in parental Kasumi-1 and 83% in parental REH cells, respectively. This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins.
Collapse
Affiliation(s)
- Anja Moldenhauer
- Institute for Transfusion Medicine and Immunehaematology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Micheva I, Thanopoulou E, Michalopoulou S, Kakagianni T, Kouraklis-Symeonidis A, Symeonidis A, Zoumbos N. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome. Br J Haematol 2004; 126:806-14. [PMID: 15352984 DOI: 10.1111/j.1365-2141.2004.05132.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Myelodysplastic syndrome (MDS) is a stem cell disorder characterized by ineffective haematopoiesis and blood cytopenias. The present study investigated the potential of bone marrow CD34(+) progenitors in MDS patients to proliferate and differentiate into dendritic cells (DCs) in a cytokine-supplemented liquid culture system and analysed the status of blood DC subsets in these patients. CD34(+) progenitors had low potential to generate DCs in vitro, as the number of DCs obtained from one CD34(+) cell was significantly lower compared with controls (median value 0.2 vs. 4, P = 0.003). In patients, the survival and proliferation of CD34(+) cells in culture was not correlated to the degree of apoptosis. Phenotypically and functionally CD34(+)-derived DCs were similar in MDS patients and normal subjects. The percentage of both circulating DC subsets in patients was extremely diminished compared with controls (myeloid DC: 0.10 +/- 0.10% vs. 0.35 +/- 0.13%, P < 0.001; plasmacytoid DC: 0.11 +/- 0.10% vs. 0.37 +/- 0.14%, P < 0.001). In cases with the 5q deletion both CD34-derived DCs and blood DCs harboured the cytogenetic abnormality. Our results indicate that, in MDS, the production of DCs is affected by the neoplastic process resulting in ineffective 'dendritopoiesis' with low blood DC precursor numbers. This quantitative DC defect probably contributes to the poor immune response against infectious agents and to the escape of the malignant clone from immune recognition with disease progression towards acute leukaemia.
Collapse
Affiliation(s)
- Ilina Micheva
- Haematology Division, Department of Internal Medicine, Patras University Medical School, Patras, Greece.
| | | | | | | | | | | | | |
Collapse
|
6
|
Moldenhauer A, Nociari M, Lam G, Salama A, Rafii S, Moore MAS. Tumor necrosis factor alpha-stimulated endothelium: an inducer of dendritic cell development from hematopoietic progenitors and myeloid leukemic cells. Stem Cells 2004; 22:144-57. [PMID: 14990854 DOI: 10.1634/stemcells.22-2-144] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Especially when exposed to inflammatory stimuli, endothelial cells (EC) have been shown to promote the maturation of monocytes into dendritic cells (DC) and the long-term proliferation of CD34+ cells by constitutive cytokine production and direct cellular contact. We therefore hypothesized that cytokine-stimulated EC would induce hematopoietic progenitor cells to develop into mature dendritic cells. To test this theory, human CD34+ cells derived from cord blood or leukapheresis products were cultured with a monolayer of either interleukin (IL)-1beta, IL-4, or tumor necrosis factor (TNF)-alpha-stimulated human umbilical cord EC. The cells in suspension were analyzed weekly over a period of 6 weeks. IL-1beta supported cell expansion, whereas IL-4 had no effect on cell expansion or DC differentiation. Only TNF-alpha-stimulated EC induced the development of mature, allostimulatory DC with a high expression of CD83, HLA-DR, CD1a, and costimulatory molecules like CD80 and CD86. Acute myeloid leukemia cells from the cell line Kasumi-1 also developed DC-like features when cocultured with TNF-alpha-stimulated EC. Direct contact between endothelial and progenitor cells increased the number of developing DC. Cell cycle analysis and apoptosis studies demonstrated a reduced G2M fraction, an increased S fraction, and a decrease in TNF-alpha-dependent apoptosis of DC developing in the presence of endothelial cells. As shown by electron and confocal microscopic studies, intimate interactions between EC and DC occurred, resulting in the internalization of the developing DC within the EC monolayer and a bidirectional exchange of proteins. We conclude that, via the action of TNF-alpha, inflamed human endothelium can induce CD34+ and leukemic cells to differentiate into dendritic cells.
Collapse
Affiliation(s)
- Anja Moldenhauer
- Institute for Transfusion Medicine, Charité, Universitätsmedizen Berlin, Berlin, Germany.
| | | | | | | | | | | |
Collapse
|